PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Procept BioRobotics Corp (PRCT) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is currently in a bearish trend, with significant negative sentiment from analysts, hedge fund selling, and ongoing legal investigations. While there is potential for long-term growth, the company's financial performance, recent downgrades, and lack of immediate positive catalysts suggest holding off on investing for now.
The technical indicators are bearish. The MACD is negatively expanding, RSI indicates the stock is oversold at 18.302, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 21.464.
The company projects strong growth in procedures for 2026, and its focus on organizational restructuring could improve long-term profitability. Analysts have provided some overweight ratings, indicating optimism for future performance.
The company missed Q4 revenue estimates by 19%, lowered its 2026 guidance, and is undergoing an investigation for potential securities fraud. Hedge funds are selling heavily, and analysts have downgraded the stock with reduced price targets. The stock fell 23.9% following the revenue miss, reflecting investor concerns.
In Q4 2025, revenue increased by 11.94% YoY to $76.38 million, but net income remains negative at -$29.85 million, despite a 58.28% YoY improvement. EPS improved to -0.53, up 51.43% YoY. Gross margin dropped to 60.63%, down 5.27% YoY, indicating profitability challenges.
Analysts are mixed but leaning negative. BofA downgraded the stock to Underperform with a price target of $20, citing profitability concerns. Wells Fargo lowered its price target to $34 but maintained an Overweight rating. Truist and UBS remain optimistic with higher price targets, but the overall trend reflects reduced confidence in the near term.
